Amryt Pharma Share Discussion Threads

[jacksonpollack] 28/10/2016 20:28

Now running at 40% below ripoff consolidation share price of 24p. Where would we be if Tendrara hadn't been sold? Probably 500% up pre consolidation share price luckily I bought into Sound energy, though not at the bottom worse luck. But I shouldn't have had too, it should have stayed here. But the buffoon bosses here in their wisdom sold it and paid a huge imparment charge. How clever

[icebreaker] 28/10/2016 14:25

€10.7 Million at 31 August 2016.

I agree that they will need more cash at some stage but I doubt there's the appetite for a placing now, particularly with no news and no impending investor presentations (that I'm aware of).

Cheers

IB

[marketgem] 28/10/2016 14:15

Do you know how much cash they have?

[dynamoo] 28/10/2016 12:01

I think papillon needs to buy some new chart software. First a bullish inverted head and shoulders, that looked more like Quasimodo after a night on the beer, and then a bullish up trend channel! Dear me.Placement on the way IMO, and probably at a discount. Sub 14p.

[jacksonpollack] 27/10/2016 21:13

Kinkell. Shame the same amount of care doesn't extend to the share price or shareholders. Ripoff consolidation, undeserved wages, ever decreasing share price all the bods have too many other interests and directorships to give this much of their time, but they want a full wage for it though.

[kinkell] 27/10/2016 20:51

JP

Drug development is a long slow tedious business - and rightly so! Great care required. Get used to it or move on would be my suggestion.

[pottermagic2310] 27/10/2016 19:23

So the theory is that these are going to sink to a low in the immediate short-term, ready for a significant uplift when some new News is released sometime in the near future. Okay, I see how that's possible BUT surely any new News has an equal probability of being Good or Bad ?

[icebreaker] 27/10/2016 17:04

Tend to agree JP - 6 months in now and very little progress to show from what I can see. A patent, the submission of the phase 3 protocol for EB to the EMA and a meeting with the FDA.

As I suspect the first two jobs would have been outsourced, I wonder which of the other high paid executives did the meeting!?

[papillon] 24/10/2016 13:01

My chart shows a short term uptrend that started in early July. Whether that uptrend continues, or breaks down, will depend on the nature of the news released by AMYT, pottermagic. I'd say the AMYT share price is anticipating good news being released and fairly soon, but I could be wrong.

To my eyes the AMYT chart looks similarly poised to back in July. Even the volume profile looks similar to that back in July. All the share price needs is good news, or the perception of good news, like back in August, to rise towards the upper trend line.

[papillon] 24/10/2016 11:15

That chart is NOT nonsense, pottermagic2310. Of course we need news! Only an idiot would suggest otherwise! The chart indicates the share price is poised to respond upwards to good news.

[pottermagic2310] 23/10/2016 15:44

Simple... there is absolutely nothing "exciting" about the share price hovering around 16-18p when they should be up at 24p. That Chart above too... NONSENSE... just draw 2 parallel lines left-to-right, downwards and either side of each of the 2 downward trends to see exactly what has really been happening. There is nothing "exciting" about made-up upwards trends or the share price being down between 16-18p... it's NONSENSE !! We need productivity, positive Development outcomes, Products achieving the next level, bankable Assets... New, News, News !!

[buffythebuffoon] 23/10/2016 15:21

RUBBISH... These are supposed to be worth around 24p/share !!

What are you talking about?

Buffy

[papillon] 20/10/2016 23:21

In a parallel lines uptrend? Looks like it!


free stock charts from uk.advfn.com

[pottermagic2310] 20/10/2016 18:05

RUBBISH... These are supposed to be worth around 24p/share !!

[currypasty] 20/10/2016 16:44

a bit of excitement this afternoon

[risk1] 19/10/2016 23:55

Potter another Classic from you

Yesterday you were going to snap up a shed full today u are thinking us pi's are stuffed

What is it to be private punter?

[gnnmartin] 19/10/2016 17:33

Further details on the purchase of Scioderm by Amicus. I skimmed Fiercebiotech and it does not look as though Scioderm had any asset other than the EB candidate (Zorblisa, SD-101), but the $841m price needs qualifying. It was "$229 million in stock and cash along with a promise of up to $618 million more for meeting a slate of milestones.". That still makes Amryt look extremely underpriced.

Another point, "TheStreet notes that Zorblisa failed its Phase IIb study, with a small subgroup of patients in the top dose achieving statistical significance compared to a placebo. That top dose is being taken into the Phase III with the blessing of regulators."

And yet another: I asked what route to market Amryt envisaged for Episalvan, and the answer is they intend to manufacture and distribute it themselves, with subcontractors for bits (packing in tubes & sterilising ... I may not remember the full story here). That is not as high risk as it might sound, because EB will be treated by a small number of specialists, so making contact with the expected market will not be as difficult as with a more general product.

The Fiercebiotech page (if ADVFN don't remove it) is

[pottermagic2310] 19/10/2016 17:28

No actual progress of any tangible value at all, on any front, just people getting paid to turn up and play with gloop in a Lab (maybe?). I have some personal experience & insight into Lab R&D and this now feels very, very stale to me. Scientists work with Facts & Figures. Good (or better) results are published, when nobody is publishing the Facts & Figures it's simply because there aren't any or they're poor (or worse!). Right now we have no Product to take to the next level and only aspirations of when something MIGHT become available, maybe. As an Investor I dearly wish for this to work out for the best... but I'm already sensing it's just another vehicle to benefit the Beneficiaries... and that doesn't include us PIs !
:-(

[bigwavedave] 19/10/2016 16:32

gnnmartin - thanks for the detailed post.

[icebreaker] 19/10/2016 16:23

Great post - thanks for the comprehensive update. There is a lot in there to digest, particularly for someone like me who has next to no understanding of the pharma market.

Very best wishes.

IB

[icebreaker] 19/10/2016 11:31

One other question for anyone here..

Rory Nealon states that the study will cost about £6 - £7 Million and will take 18 months. In addition, we are currently working to a £500k a month cash burn. Our cash balance is about £10M. That is not going to get us anywhere near 2018 based on those numbers. Have I missed something?

Thanks in advance.

IB